

federally funded health care program. If resolution results in conviction, debarment or exclusion of the individual, the laboratory should terminate its employment of that individual or company.

Conclusion

These basic recommended elements coupled with other published regulations and guidelines are the foundation for a comprehensive compliance plan for clinical laboratories. On advice from in-house counsel and senior management, clinical laboratories should add to or modify these elements to better reflect the corporate structure of the laboratory, its mission, and its employee composition. The OIG believes that by implementing an effective compliance plan, a laboratory will achieve better quality control of claims submission and reduce the risk of future criminal and civil liabilities.

Dated: February 24, 1997.

June Gibbs Brown,

Inspector General.

[FR Doc. 97-5192 Filed 2-28-97; 8:45 am]

BILLING CODE 4150-04-P

National Institutes of Health

Notice of Meeting of the Advisory Committee on Blood Safety and Availability

Pursuant to Pub. L 92-463, notice is hereby given of the meeting of the Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, March 20-21, 1997. This meeting will be held at the National Institutes of Health, Warren G. Magnuson Clinical Center, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 8:30 a.m. on March 20 to adjournment on March 21. On March 20, the Committee will discuss hepatitis C virus (HCV) infection, its occurrence following blood transfusion, other epidemiology of HCV infection and appropriate ways of approaching the public health aspects of this infection. On March 21, the Committee will address multiple aspects of the theoretical possibility that Creutzfeldt-Jakob disease (CJD) can be transmitted by blood transfusion. For each topic, a time will be set aside for the public to comment. Prospective speakers should notify the Executive Secretary for this meeting of their wish to present and should plan for no more than 5 minutes of comments.

Contact: Paul R. McCurdy, M.D., Acting Executive Secretary, Advisory Committee on Blood Safety and Availability, Director, Blood Resources Program, DBDR-MS-7950, NHLBI, NIH, Bethesda, Maryland 20892-7950. Phone: 301/435-0065; Fax 301/480-1060; E-Mail: paul-mccurdy@nih.gov.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

Dated: February 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-5164 Filed 2-28-97; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee H—Clinical Trials Subcommittee.

Date: April 8-9, 1997.

Time: 8 a.m.

Place: Buffalo Marriott, 1340 Millersport Highway, Amherst, New York 14221.

Contact Person: John L. Meyer, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, 6130 Executive Blvd. Room 611C, Bethesda, Md 20892, Telephone: 301-496-7721.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower, 93.399, Cancer Control)

Dated: February 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-5166 Filed 2-28-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meetings:

Name of SEP: NIAMS Supplemental (Teleconference).

Date: March 18, 1997.

Time: 11:00 a.m.-12:30 p.m.

Place: Natcher Building, 45 Center Drive, Rm 5AS-25U.

Contact Person: Aftab A. Ansari, Ph.D., Natcher Building, 45 Center Drive, Rm 5AS-25U, Bethesda, Maryland 20892-6500, Telephone: 301-594-4952.

Name of SEP: NIAMS Program Project.

Date: April 1, 1997.

Time: 8:30 a.m.-adjournment.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland 20814.

Contact Person: Aftab A. Ansari, Ph.D., Natcher Building, 45 Center Drive, Rm 5AS-25U, Bethesda, Maryland 20892-6500, Telephone: 301-594-4952.

Purpose/Agenda: To evaluate and review research grant applications.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.846, Project Grants in Arthritis, Musculoskeletal and Skin Diseases Research], National Institutes of Health, HHS)

Dated: February 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-5163 Filed 2-28-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: March 17, 1997.

Time: 11 a.m.

Place: Parklawn, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857.